Novartis Pharma N.V.
Novartis Pharma N.V., commonly referred to as Novartis, is a leading global healthcare company headquartered in Basel, Switzerland (BE). Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has established itself as a key player in the pharmaceutical industry, focusing on innovative medicines, generics, and biosimilars.
With a strong presence in major operational regions including North America, Europe, and Asia, Novartis is renowned for its commitment to research and development. The company’s core products encompass a wide range of therapeutic areas, including oncology, cardiology, and immunology, distinguished by their cutting-edge technology and patient-centric approach.
Recognised for its significant contributions to healthcare, Novartis consistently ranks among the top pharmaceutical companies globally, driven by a robust pipeline and a dedication to improving patient outcomes.
+91 vs industry average
Novartis Pharma N.V.’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Novartis Pharma N.V.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Fruit and Vegetable Products is among the most carbon-intensive industries
Industry performance
The Fruit and Vegetable Products industry has reduced its overall emissions by 19% since 2018
Reported emissions
No reported emissions data is available for Novartis Pharma N.V. yet.
Novartis Pharma N.V.'s reported carbon emissions
Novartis Pharma N.V., headquartered in Belgium (BE), currently does not have specific emissions data available for the most recent year. The company is a current subsidiary of Novartis AG, which cascades its climate commitments and emissions data.
As part of its climate strategy, Novartis AG has set various reduction targets and initiatives that influence Novartis Pharma N.V. These include commitments under the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded to Novartis Pharma N.V. from its parent company. However, specific reduction targets or achievements for Novartis Pharma N.V. have not been detailed.
The absence of direct emissions data highlights the need for ongoing transparency and accountability in corporate climate commitments. Novartis Pharma N.V. is expected to align with the broader sustainability goals set by Novartis AG, focusing on reducing its carbon footprint and contributing to global climate action.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Novartis Pharma N.V.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Novartis Pharma N.V. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Novartis AG
Carbon Disclosure Project
Inherited from Novartis AGThe Climate Pledge
Inherited from Novartis AGUN Global Compact Climate Champions initiative
RE 100
Inherited from Novartis AGClimate Action 100
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Novartis Pharma N.V. yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project